Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with Intellectual Disability
Authors:
- Cecile PaganCPCecile Pagan
- Hany Goubran BotrosHBHany Goubran Botros
- Karine PoirierKPKarine Poirier
- Anne DumaineADAnne Dumaine
- Stéphane JamainStéphane Jamain
- Sarah MorenoSMSarah Moreno
- Arjan de BrouwerABArjan de Brouwer
- Hilde Van EschHEHilde Van Esch
- Richard DelormeRDRichard Delorme
- Jean-Marie LaunayJLJean-Marie Launay
- Andreas TzschachATAndreas Tzschach
- Vera KalscheuerVKVera Kalscheuer
Open Access
- 20 January 2011
- journal article
- research article
- Published by Springer Nature in BMC Medical Genetics
- Vol. 12 (1) , 17
Abstract
Background: Intellectual disability (ID) is frequently associated with sleep disorders. Treatment with melatonin demonstrated efficacy, suggesting that, at least in a subgroup of patients, the endogenous melatonin level may not be sufficient to adequately set the sleep-wake cycles. Mutations in ASMT gene, coding the last enzyme of the melatonin pathway have been reported as a risk factor for autism spectrum disorders (ASD), which are often comorbid with ID. Thus the aim of the study was to ascertain the genetic variability of ASMT in a large cohort of patients with ID and controls. Methods: Here, we sequenced all exons of ASMT in a sample of 361 patients with ID and 440 controls. We then measured the ASMT activity in B lymphoblastoid cell lines (BLCL) of patients with ID carrying an ASMT variant and compared it to controls. Results: We could identify eleven variations modifying the protein sequence of ASMT (ID only: N13H, N17K, V171M, E288D; controls only: E61Q, D210G, K219R, P243L, C273S, R291Q; ID and controls: L298F) and two deleterious splice site mutations (IVS5+2T>C and IVS7+1G>T) only observed in patients with ID. We then ascertained ASMT activity in B lymphoblastoid cell lines from patients carrying the mutations and showed significantly lower enzyme activity in patients carrying mutations compared to controls (p = 0.004). Conclusions: We could identify patients with deleterious ASMT mutations as well as decreased ASMT activity. However, this study does not support ASMT as a causative gene for ID since we observed no significant enrichment in the frequency of ASMT variants in ID compared to controls. Nevertheless, given the impact of sleep difficulties in patients with ID, melatonin supplementation might be of great benefit for a subgroup of patients with low melatonin synthesis.Keywords
This publication has 26 references indexed in Scilit:
- Identification of Pathway-Biased and Deleterious Melatonin Receptor Mutants in Autism Spectrum Disorders and in the General PopulationPLOS ONE, 2010
- Mutation screening of melatonin-related genes in patients with autism spectrum disordersBMC Medical Genomics, 2010
- Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta‐analysisDevelopmental Medicine & Child Neurology, 2009
- Individual Differences in the Amount and Timing of Salivary Melatonin SecretionPLOS ONE, 2008
- When Clocks Go Bad: Neurobehavioural Consequences of Disrupted Circadian TimingPLOS Genetics, 2008
- Is ASMT a susceptibility gene for autism spectrum disorders? A replication study in European populationsMolecular Psychiatry, 2007
- Abnormal melatonin synthesis in autism spectrum disordersMolecular Psychiatry, 2007
- The basic physiology and pathophysiology of melatoninSleep Medicine Reviews, 2005
- Generation of the Melatonin Endocrine Message in Mammals: A Review of the Complex Regulation of Melatonin Synthesis by Norepinephrine, Peptides, and Other Pineal TransmittersPharmacological Reviews, 2003
- Sleep problems in children with mental handicapJournal of Intellectual Disability Research, 1991